Woman in an outdoor settingWoman in an outdoor settingteal triangle graphic

Medicines & Focus

Innovation Focused
on Complex Diseases

Therapeutic Areas of Focus

We are inspired by the courage and determination of individuals living with complicated and often difficult-to-treat diseases. We have a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurological disorders and cancer.


Disease Areas

Addiction

We have been at the forefront of addiction medicine for more than a decade, seeking to help people living with alcohol dependence and opioid dependence.

Serious Mental Illness

We are committed to addressing unmet needs in serious mental illness through the development of therapeutic options to support adults living with schizophrenia and bipolar I disorder.

Cancer

We are actively researching new immuno-oncology agents for cancer patients in tumor types where we see significant need and opportunity for new treatment options.

We Develop Innovative Medicines 

Alkermes’ technologies and discoveries have contributed to the development of medicines that have helped shape the treatment landscape, and form the basis for our current investigational products in a range of disease areas.

Proprietary U.S. Medicines

Our mission to make innovative medicines that may help address unmet patient needs underlies our work. Our portfolio of proprietary commercial products focuses on chronic, highly prevalent conditions that represent some of the most challenging health issues of our time.


Our proprietary U.S. medicines

Product Candidates in Development

Our research and development efforts are focused on the pursuit of potential new medicines that build on our heritage in neuroscience and, as scientific opportunities present themselves, advancement of our research into important new areas such as immuno-oncology.


Our R&D efforts

Third-Party Medicines

Our proprietary technologies are incorporated into third-party medicines that are commercialized by global pharmaceutical companies for people living with a range of series diseases.
Learn more about third-party medicines that utilize our proprietary technologies.

U.S. medicines   EU medicines

Man in a conference room at Alkermesteal triangle graphic

Commitment to patients runs very deep at Alkermes. It starts when we discover new ideas in our labs, continues as we conduct clinical trials, make our medicines, educate stakeholders about unmet needs and support those who take our medicines.